Table 1 Clinicopathological characteristics of patients with small intestinal neuroendocrine tumors subjected to miRNA profiling

From: miRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival

Case number

Age at diagnosis

Gender

Grade (WHO 2010)f

Mitotic count (per 10 HPF)

Ki67, %

Stage (TNM 7th edn)g

Follow-up, months

Current status

Primary surgery

Tumor site for miRNA profiling

1

64

F

G1

0.4

0.5

IV

40

DWD

Yes

P

2

68

M

G2

0.2

5.3

IV

16

DWD

Yes

P

3

59

M

G1

1.4

2

IIIB

110

NED

Yes

P

4

58

F

G1

0.2

0.7

IV

168

AWD

Yes

P

5

74

F

G1

< 0.2

0.5

IV

78

DWD

Yes

P

6

68

M

G1

< 0.2

0.4

IV

18

DWD

Yes

P

7a

53

M

G1

< 0.2

0.5

IV

61

DWD

Yes

P

   

G1

0.4

1

   

Yes

L

8b

80

F

G1

< 0.2

0.5

IV

142

DWD

Yes

P

   

G1

0.4

1.1

   

Yes

L

9

81

F

G1

0.2

2

IV

35

DWD

Yes

P

10

42

F

G1

0.6

1.9

IV

201

AWD

Yes

P

11

79

M

G1

0.2

0.7

IV

29

DWD

Yes

P

12

49

M

G2

1.4

6

IV

5

DWD

Yes

P

13c

71

F

G1

< 0.2

1.5

IV

60

DWD

Yes

P

   

G2

3.8

5.2

    

L

14d

56

F

G1

< 0.2

0.4

IV

12

DWD

Yes

P

   

G3

8.4

30.4

   

Yes

L

15e

73

M

G2

1

3.4

IV

6

DWD

Yes

P

   

G2

5.5

8.6

   

Yes

L

16

60

M

G1

1

1

IV

35

DWD

Yes

L

17

75

F

G2

0.6

9.9

IV

32

DWD

Yes

L

18

53

M

G1

0.4

2.6

IIIB

142

AWD

Yes

L

19

47

F

G2

0.6

5.5

IIIB

94

AWD

Yes

L

20

74

M

G2

2.2

4.7

IV

11

DWD

Yes

L

21

61

F

G2

4.4

16.7

IV

4

DWD

Yes

L

22

70

F

G2

7

11.7

IV

13

DWD

Yes

L

23

73

F

G2

4.6

11.2

IV

19

DWD

Yes

L

24

63

M

G1

< 0.2

0.6

IV

163

AWD

Yes

P

25

53

F

G1

< 0.2

0.4

IV

155

AWD

Yes

LN

26

64

M

G1

0.6

0.2

IV

94

DWD

Yes

L

27

64

F

G1

0.4

0.7

IV

116

NED

Yes

L

28

71

M

G1

< 0.2

2.1

IV

82

DWD

Yes

L

29

61

F

G1

< 0.2

0.7

IV

98

AWD

Yes

L

30

51

M

G1

< 0.2

0.9

IV

105

AWD

Yes

L

31

71

M

G2

2.2

1.6

IV

124

DWD

Yes

L

32

56

F

G1

0.2

1.3

IV

42

DWD

Yes

L

33

74

M

G1

0.2

0.3

IV

34

DWD

Yes

L

34

70

M

G1

< 0.2

0.6

IV

91

AWD

Yes

L

35

75

F

G1

0.4

2.4

IV

40

DWD

Yes

L

36

59

M

G1

0.2

0.6

IV

71

DWD

Yes

LN

37

72

M

G1

< 0.2

0.8

IV

130

AWD

Yes

L

  1. Abbreviations: AWD, alive with disease; DWD, dead with disease; F, female; HPF, high power fields; L, liver metastases; LN, lymph node metastases; M, male; NED, no evidence of disease; P, primary tumor. a, b, c, d, and e; cases with paired tumor samples (primary and liver metastases), f WHO 2010 (see ref. [19]), gTNM 7th edn (see ref. [20])